We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
  • Drug Products
    • Books
    • Books Library
    • Events
    • Form 483s
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
  • Device Products
    • Books
    • Books Library
    • Events
    • Form 483s
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Public Citizen Sues FDA for Inaction on Boxed Warning Petition

Public Citizen Sues FDA for Inaction on Boxed Warning Petition

May 6, 2019

Public Citizen is suing the FDA over its failure to act on a petition seeking a boxed warning on labels of dopamine promoters.

The consumer advocacy group’s 2016 petition called for black box warnings for six dopamine agonist drugs—apomorphine, bromocriptine, cabergoline, pramipexole, ropinirole and rotigotine—used for treating restless leg syndrome, Parkinson’s disease and other conditions.

Public Citizen said that the drugs could cause compulsive or uncontrollable behaviors in patients, urging the agency to issue letters to doctors and patients warning them about the risks.

“Patients taking a dopamine agonist drug may have up to a twenty-fold greater risk of impulse-control problems and compulsive behaviors, including pathological gambling and insatiable shopping or eating, than patients not using these medications,” the group said.

In a complaint filed April 29 in the U.S. District Court for the District of Columbia, the group calls for a decision on the petition, noting the FDA has failed to either grant or deny the petition filed more than two and a half years ago.

The FDA sent an acknowledgment letter in June 2016 and an interim response letter in December 2016 declaring that the issue was “not yet resolved,” but has taken no action since then despite the serious risks, the group said.

View today's stories

Pharmaceuticals Regulatory Affairs

Upcoming Events

  • 10Jan

    Organizing Data and Document Archives: Finding a Needle in a Haystack for FDA Inspections

  • 12Feb

    Increase Compliance, Reduce Risk with Integrated Digital Solutions: Create a Connected System and Streamline...

  • 17Mar

    FDA Data Integrity: For Device and Pharma Firms, and Their Suppliers

  • 19Mar

    SOPs and Policies for the 21st Century: Why Less is More

  • 20Apr

    17th Annual Medical Device Quality Congress

Featured Products

  • Biological-risk-eval-and-mngmnt-for-md-130x160

    Biological Risk Evaluation and Management for Medical Devices

  • Gmp-inspection-preparation-checklist-130x160

    GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

  • 483sonline-logo-430x250

    483sOnline.com Your Personal Pre-inspection Toolkit

  • Globalmarketimage

    International Devices and Diagnostics Monitor

  • Cryolife_logo

    CryoLife’s Thoracoabdominal Stent Graft Receives CE Mark

  • Patentstablabel

    House Judiciary Committee Advances Patent Abuse Legislation

New!

17th Medical Device Quality Congress

Learn More Here
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA.

Phone 703.538.7600 – Fax 703.538.7676 – Toll free 888.838.5578.

Copyright © 2019. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing